Publicatie

Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patientU+2010reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUSU+201024 and SINUSU+201052 studies